Top Indian Pharmaceutical Companies by Market Capitalisation

Pharmaceutical stocks have experienced significant upward momentum, demonstrating substantial growth in both domestic and international markets. The Indian pharmaceutical market has become robust and vibrant, largely due to the success of “Made in India” medicines, which have contributed to some of the best-performing pharma stocks.

India holds a prominent position as a major producer of high-quality and affordable generic drugs. Globally, it supplies approximately 20% of the demand for pharmaceuticals in terms of volume. One of India’s key strengths in the pharmaceutical industry is its traditional ability to rapidly produce generic drugs in a cost-effective manner.

The pharmaceutical industry in India has a significant advantage in producing generic branded drugs. In fact, India has the most US FDA-approved manufacturing plants for generic drugs outside of the United States.

This achievement is a testament to India’s strong position in the global pharmaceutical market. Furthermore, local companies have found their unique areas of expertise by investing early and developing new drug formulations.

In this article, we will closely examine the leading pharmaceutical companies. The recent release of quarterly financial results has drawn considerable attention to pharma stocks. We will offer a brief overview of their performance, and the list is arranged based on market capitalisation.

 Some of the few companies reported their June quarter recently, namely Cipla, and Syngene International. The stock prices of these companies are reflecting the positive impact of their strong financial performance. However, it’s worth noting that today the market is witnessing some profit booking.

Let’s look at the recent results of two companies. Cipla’s revenue from operations increased by 17.74% year on year (YoY), reaching Rs 6329 Crore from Rs 5375 Crore. The company’s operating profit stood at Rs 1494 Crore, with a margin of 24%. Cipla’s net profit amounted to Rs 998 Crore.

As for Syngene International, their revenue from operations witnessed a YoY surge of 25.38%, rising from Rs 644 Crore to Rs 808 Crore. The company’s operating profit was recorded at Rs 212 Crore, with a margin of 26%. Syngene International’s net profit stood at Rs 93 Crore.

Today, both these companies’ stocks are showing strong bullish movement in the intraday session. Cipla’s stock is currently trading at Rs 1169.75, up by 9.43%, while shares of Syngene International are trading at Rs 808, up by 6.08% from the previous day’s closing price on the BSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet, and is subject to changes. Please consult an expert before making related decisions.